William Blair Issues Pessimistic Outlook for TARS Earnings

Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) – Research analysts at William Blair dropped their Q1 2025 EPS estimates for Tarsus Pharmaceuticals in a report issued on Tuesday, February 25th. William Blair analyst L. Hanbury-Brown now forecasts that the company will post earnings of ($0.82) per share for the quarter, down from their previous estimate of ($0.72). The consensus estimate for Tarsus Pharmaceuticals’ current full-year earnings is ($3.17) per share. William Blair also issued estimates for Tarsus Pharmaceuticals’ Q1 2025 earnings at ($0.82) EPS, Q2 2025 earnings at ($0.52) EPS, Q3 2025 earnings at ($0.32) EPS, Q3 2025 earnings at ($0.32) EPS, Q4 2025 earnings at ($0.05) EPS, Q4 2025 earnings at ($0.05) EPS, FY2025 earnings at ($1.70) EPS and FY2025 earnings at ($1.70) EPS.

A number of other equities research analysts have also recently issued reports on TARS. HC Wainwright reaffirmed a “buy” rating and issued a $73.00 price objective on shares of Tarsus Pharmaceuticals in a research note on Wednesday. Guggenheim restated a “buy” rating and set a $78.00 price target (up from $75.00) on shares of Tarsus Pharmaceuticals in a research report on Monday. Oppenheimer raised their price objective on Tarsus Pharmaceuticals from $65.00 to $72.00 and gave the company an “outperform” rating in a research note on Wednesday, January 22nd. The Goldman Sachs Group boosted their target price on Tarsus Pharmaceuticals from $36.00 to $41.00 and gave the company a “neutral” rating in a research note on Friday, November 15th. Finally, Barclays reduced their price target on Tarsus Pharmaceuticals from $62.00 to $60.00 and set an “overweight” rating on the stock in a research report on Wednesday. One research analyst has rated the stock with a hold rating, five have given a buy rating and one has issued a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the company presently has an average rating of “Buy” and an average target price of $61.33.

Tarsus Pharmaceuticals Stock Up 2.3 %

Shares of TARS opened at $43.55 on Friday. The firm has a market cap of $1.66 billion, a P/E ratio of -11.43 and a beta of 1.01. Tarsus Pharmaceuticals has a 1 year low of $20.08 and a 1 year high of $57.28. The stock has a 50 day simple moving average of $51.14 and a two-hundred day simple moving average of $43.00. The company has a debt-to-equity ratio of 0.30, a current ratio of 5.42 and a quick ratio of 5.38.

Tarsus Pharmaceuticals (NASDAQ:TARS) last posted its quarterly earnings data on Tuesday, February 25th. The company reported ($0.60) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.68) by $0.08. The firm had revenue of $66.41 million during the quarter, compared to analysts’ expectations of $58.80 million. Tarsus Pharmaceuticals had a negative return on equity of 55.86% and a negative net margin of 103.64%.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently bought and sold shares of the business. JPMorgan Chase & Co. increased its stake in shares of Tarsus Pharmaceuticals by 2,088.8% during the third quarter. JPMorgan Chase & Co. now owns 440,167 shares of the company’s stock valued at $14,477,000 after buying an additional 420,057 shares during the period. Creative Planning bought a new position in Tarsus Pharmaceuticals in the 3rd quarter worth $362,000. Vestal Point Capital LP purchased a new stake in shares of Tarsus Pharmaceuticals in the 3rd quarter worth about $7,565,000. Jennison Associates LLC boosted its stake in shares of Tarsus Pharmaceuticals by 14.8% during the 4th quarter. Jennison Associates LLC now owns 2,500,132 shares of the company’s stock valued at $138,432,000 after purchasing an additional 321,552 shares in the last quarter. Finally, Verition Fund Management LLC purchased a new position in shares of Tarsus Pharmaceuticals during the third quarter valued at about $763,000. Institutional investors own 90.01% of the company’s stock.

About Tarsus Pharmaceuticals

Tarsus Pharmaceuticals, Inc, a commercial stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutic candidates for eye care in the United States. The company's lead product candidate is XDEMVY, a novel therapeutic for the treatment of blepharitis caused by the infestation of Demodex mites, as well as to treat meibomian gland disease.